...
首页> 外文期刊>HIV medicine >Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.
【24h】

Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.

机译:在接受基于蛋白酶抑制剂的高活性抗逆转录病毒疗法的HIV-1感染患者中,经常同时使用胃酸减少剂。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: The aim of the study was to assess the frequency of the concurrent use of gastric acid-reducing agents among HIV-1-infected patients treated with highly active antiretroviral therapy (HAART) combinations. METHODS: An anonymous, semistructured, self-administered questionnaire was consecutively distributed among HIV-1-infected patients at routine visits to specialized HIV clinics. The questionnaire contained 17 items asking specifically for information on current antiretroviral treatments and the use of gastric acid-reducing agents as well as demographic data. RESULTS: A total of 424 patients in 12 centres participated in the study: 85% were male, 88% were of German nationality, 82% were >35 years of age and 201 (47.4%) were receiving a protease inhibitor (PI)-containing HAART regimen. Of these, 74 (37%) had received an acid-reducing drug within the previous 6 months and 43 (58%) were currently still on it. Two-thirds of patients (64.9%) were treated with proton-pump inhibitors (pantoprazole, omeprazole or esomeprazole) and 56% of patients on PI-containing regimens had been taking these drugs for longer than 2 months and up to a maximum of 3 years. The majority of patients (77%) had received the prescription for the acid-reducing drugs from their HIV specialist and the remaining patients had received over the counter (OTC) medication or prescriptions from other medical personnel. CONCLUSIONS: A substantial subset of patients treated with HAART combinations, including those on PI-containing regimens, were using concomitant acid-reducing drugs, most often proton-pump inhibitors. As negative drug-drug interactions between some of the (boosted) PIs and gastric acid-reducing agents have recently been reported, HIV physicians should take this into account when prescribing PI-containing HAART combinations in order to avoid an additional risk of treatment failure.
机译:目的:本研究的目的是评估在接受高活性抗逆转录病毒疗法(HAART)治疗的HIV-1感染患者中同时使用胃酸减少剂的频率。方法:在一家专门的HIV诊所进行例行检查时,在一名HIV-1感染患者中连续分发了一个匿名,半结构,自我管理的问卷。问卷包含17个项目,专门询问有关当前抗逆转录病毒治疗和胃酸减少剂的使用的信息以及人口统计数据。结果:12个中心的424名患者参加了研究:男性85%,德国国籍88%,> 35岁年龄组的82%,以及201(47.4%)位接受蛋白酶抑制剂(PI)-包含HAART方案。其中,有74个(37%)在过去6个月内曾接受过减酸药,目前有43个(58%)仍在服用。三分之二(64.9%)的患者接受了质子泵抑制剂(pan托拉唑,奥美拉唑或埃索美拉唑)治疗,接受PI方案的患者中有56%服用这些药物的时间超过2个月,最多3个月年份。大多数患者(77%)从其HIV专家那里收到了减酸药处方,其余患者从其他柜台接受了非处方药(OTC)药物或处方。结论:大量接受HAART组合治疗的患者(包括采用PI方案的患者)正在使用伴随降酸的药物,最常使用的是质子泵抑制剂。由于最近已经报道了某些(增强的)PI与胃酸减少剂之间的药物-药物相互作用为负,HIV医师在开处方含PI的HAART组合时应考虑到这一点,以避免治疗失败的额外风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号